1226548-51-1Relevant articles and documents
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer
Lin, Shu-Yu,Chang Hsu, Yung,Peng, Yi-Hui,Ke, Yi-Yu,Lin, Wen-Hsing,Sun, Hsu-Yi,Shiao, Hui-Yi,Kuo, Fu-Ming,Chen, Pei-Yi,Lien, Tzu-Wen,Chen, Chun-Hwa,Chu, Chang-Ying,Wang, Sing-Yi,Yeh, Kai-Chia,Chen, Ching-Ping,Hsu, Tsu-An,Wu, Su-Ying,Yeh, Teng-Kuang,Chen, Chiung-Tong,Hsieh, Hsing-Pang
supporting information, p. 10108 - 10123 (2019/11/29)
Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol
Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors
-
Page/Page column 49-50, (2010/06/11)
Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.